Mentor Capital, Inc. - Advaxis Added To Cancer Immunotherapy Index

Mentor Capital, Inc. and CI Companies

$10M Cancer Assets
3M Basic Shares

About Mentor Capital About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance Investor's Corner (Contract) Analysts' Coverage $5/Share - Sr. Securities Analyst Cancer Imm Index Information Visit Portfolio Companies

Trading Chart

news releases

Back | Print | Bookmark

Advaxis Added To Cancer Immunotherapy Index

San Diego, CA--February 15, 2011--Mentor Capital, Inc. (OTC Markets:MNTR) reports that Advaxis, Inc. (OTCBB:ADXS) has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index. As with all Index companies, a portion of Advaxis shares will be purchased and included in the Mentor Capital portfolio for tracking. Cancer Immunotherapy Index creator and Mentor Capital, CEO, Chester Billingsley notes that only the historic Advaxis involvement in infectious disease and allergic syndromes delayed the earlier inclusion of Advaxis into Mentor’s cancer-only focused Index.

“The beauty of the Advaxis approach is that they can tag various cancer markers like Her-2 or PSA to small, common, everyday bacteria that the human body is very used to attacking. The bacteria is weakened by a factor of 10,000 and easily defeated and engulfed. This directly introduces the attached cancer antigens inside the immune system cells. That Trojan Horse approach simultaneously activates all aspects of the immune system and points it at the cancer cells that carry the marker,” explains Billingsley. Following this approach, Advaxis reports it has nine distinct cancer fighting constructs in various stages of development covering cervical, breast, head & neck, and prostate cancers.

Mentor Capital created the Cancer Immunotherapy Index in July 2009. The company and its shareholders aim to provide socially responsible funding for these and other leading edge cancer therapy and development companies. The best non-profit and university breakthroughs must be developed and tested by these exact same firms before they can be released into medical use. Advaxis Chairman/CEO Thomas A. Moore comments, “The Mentor Index has long-been a prestigious cross section of the top immunotherapy companies. We at Advaxis are delighted to be part of this closely-watched group of truly innovative biotech firms.”

The Mentor Capital Cancer Immunotherapy Index companies include: Dendreon (NASDAQ:DNDN), Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), Oncothyreon (NASDAQ:ONTY), Agenus (NASDAQ:AGEN), Biovest International (OTC Markets:BVTI), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), CEL - SCI Corp. (AMEX:CVM), Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Advaxis, Inc.

The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.

__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

↑ Back to Top

The Mentor Capital Cancer Immunotherapy Index ^©

For Email Marketing you can trust

See Actual Cancer
Vaccine Results!

Home

Changing Assets & Acquisitions

Warrant Information

Chairman's Letters

◦	4,000% Increase in Four Months Triggers Early 2012 Annual Meeting
◦	Bringing It All Together To Win In The Cancer Fight (2011)
◦	Welcome To The Team Leading The Cancer Fight (2010)

Medicine, Science & The Economy

◦	Sunlight Explains Japan Radiation Risk

Press Releases

◦	Mentor Capital Cancer Immunotherapy Index Gains 47% During First Quarter
◦	Mentor Capital on High Growth Path with Planned $32 Million Health Care IT Investment
◦	Mentor Capital to Discuss Major Cancer Funding, Low PE and Warrant Call at April 29 Shareholder Meeting
◦	MNTR Earnings Exceed its Share Price for the Low PE Stock of this Socially Responsible Cancer Funding Company
◦	Mentor Capital Acquires 50 Percent of Brighter Day Health For $5M
◦	Mentor Capital Begins its 2012 Cancer Roll-up Strategy
◦	MNTR Acquires 30 Percent of European Cancer Vaccine for $4.71 Million
◦	Mentor Capital Adds to European Cancer Portfolio with AGI Biopharmaceuticals Melanoma Vaccine
◦	Mentor Capital Reports Mid-Year Profits for 2011
◦	Mentor Capital Initiates Discussions for Potential Merger
◦	Mentor Capital Seeks Funding Partners as Neutron Cancer Therapy Accelerates
◦	Cancer Immunotherapy Index Outpaces Biotechs
◦	Increased Chinese and International Visitors to Mentor Capital Site
◦	CEO Purchases an Additional 3.14% of MNTR Shares
◦	MNTR Drafts Five Cancer Funding Contracts for $40 Million
◦	MNTR Screens Cancer Companies For Investment At ASCO
◦	$125 Million for Socially Responsible Direct Cancer Funding
◦	Advaxis Added To Cancer Immunotherapy Index
◦	MNTR In Discussion With Breast Cancer Immunotherapy Company
◦	Nobel Laureate Reinforces the Mentor Capital Strategy to Fund Only Leading-edge Cancer Science
◦	Mentor Capital to Expand Funding Bridge Over Cancer Development Gap
◦	Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval
◦	MNTR Sees Shift To Public Acceptance
◦	Cancer Index at New High with 12 Yr Exclusive Period in Health Bill
◦	Provectus Pharmaceuticals (PVCT) added to Cancer Immunotherapy Index
◦	MNTR Invests in 10 Cancer Index Companies
◦	MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund
◦	2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR
◦	MNTR Presents in NYC
◦	QI Announces MNTR
◦	MNTR Calls $3 Million Tranche
◦	MNTR Initiates Trading

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

Safe Harbor Statement Site Map